Form 8-K Sage Therapeutics, Inc. For: Nov 09
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Chardan Capital Markets Upgrades Sage Therapeutics (SAGE) to Buy
November 10, 2017 8:16 AM ESTChardan Capital Markets upgraded Sage Therapeutics (NASDAQ: SAGE) from Neutral to Buy with a price target of $140.00 following phase III Hummingbird data for brexanolone in PPD.
Analyst Gbola Amusa see a read-across from brexanolone in PPD to other vast-market indications, like MDD, Sage... More
Sage Therapeutics (SAGE) PT Raised to $135 at Cowen
November 9, 2017 3:20 PM ESTCowen raised its price target on Sage Therapeutics (NASDAQ: SAGE) to $135.00 (from $90.00) while maintaining a Outperform rating following positive top-line data from the Ph3 HUMMINGBIRD trials of brexanolone in moderate and severe PPD.
Analyst Ritu Baral is optimistic that... More
Sage Therapeutics (SAGE) PT Raised to $105 at Stifel
November 9, 2017 12:43 PM ESTStifel raised its price target on Sage Therapeutics (NASDAQ: SAGE) to $105.00 (from $91.00) while maintaining a Buy rating after the company reported positive top-line data from P3 Hummingbird trials with brexanolone (i.v. formulation) in postpartum depression (PPD).
Analyst Adam Walsh this... More
